Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients

Rebecca Acquah; Erika Mohr-Holland; Johnny Daniels; Jennifer Furin; Marian Loveday; Vanessa Mudaly; Anja Reuter

doi:10.1097/INF.0000000000003069

Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients

Pediatr Infect Dis J. 2021 May 1;40(5):e191-e192. doi: 10.1097/INF.0000000000003069.

Authors

Rebecca Acquah¹, Erika Mohr-Holland¹, Johnny Daniels¹, Jennifer Furin², Marian Loveday³, Vanessa Mudaly⁴, Anja Reuter¹

Affiliations

¹ From the Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa.
² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA.
³ Health Systems Research Unit, South African Medical Research Council, KwaZulu-Natal, South Africa.
⁴ Department of Health, Province of the Western Cape, Cape Town, South Africa.

Abstract

This brief report presents a series of 5 pregnant women treated for rifampicin-resistant tuberculosis with the novel drugs bedaquiline, delamanid, and linezolid as part of an optimized backbone regimen and reviews the outcomes of the children born to them. Although the case series is small, all children had excellent birth outcomes suggesting pregnant women should not be denied access to novel therapies for RR-TB.

Publication types

Case Reports

MeSH terms

Adult
Antitubercular Agents / therapeutic use*
Child Health
Child, Preschool
Diarylquinolines / therapeutic use*
Female
Humans
Infant
Infant Health
Linezolid / therapeutic use*
Nitroimidazoles / therapeutic use*
Oxazoles / therapeutic use*
Pregnancy
Pregnancy Outcome
Pregnant Women*
South Africa / epidemiology
Tuberculosis, Multidrug-Resistant / drug therapy*
Young Adult

Substances

Antitubercular Agents
Diarylquinolines
Nitroimidazoles
OPC-67683
Oxazoles
bedaquiline
Linezolid